The use of laser vaporization for the treatment of benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Results of use of UroBeam laser diode in 72 patients with benign prostatic hyperplasia (BPH) were analyzed. Average prostate volume was 67,29+26,72 cm3, the duration of vaporization - 69,2±23,7 min. Blood loss was minimal. In the period from 2 weeks to 4 months after surgery, 9 patients have developed acute urinary retention. In the early postoperative period, acute prostatitis was diagnosed in 7 patients and was jugulated using drug treatment. The laser vaporization of BPH led to a three-fold reduction in the severity of urinary disorders and increase the urinary flow rate. The combination of laser vaporization of the prostate with transurethral resection of the prostate allow to improve the recovery of urination after surgery

Full Text

Restricted Access

References

  1. Roehrborn C.G., Siami P., Barkin J. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010;57(1):123-131.
  2. Complication of urologic surgery: prevention and management / ed. Samir S. Taneja. - 4th ed. 2010.
  3. Reich O., Gratzke C., Stief C.G. Techniques and LongTerm Results of Surgical Procedures for BPH. Eur. Urol. 2006;49(6):970-978.
  4. Rassweiler J., Teber D., Kuntz R. et al. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur. Urol. 2006;50(5):969-979.
  5. Yu X., Elliott S.P., Wilt T.J. et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol. 2008;180(1):241-245.
  6. Hauser J., lselin C.E. An innovative laser for the minimally invasive treatment of benign prostatic hyperplasia. Rev. Med. Suisse. 2012;8(365):2340-2343.
  7. Ding H., Du W., Lu Z.P. et al. Photoselective green-light laser vaporisation vs. TURP for BPH: meta-analysis. Asian. J Androl. 2012; 14(5):720-725.
  8. Chen C.H., Lin S.E., Chiang P.H. Outcome of GreenLight HPS laser therapy in surgically high-risk patients. Lasers. Med. Sci. 2012 Nov 23.
  9. Elhilali M.M. Overview of interventional treatment options for benign prostatic hyperplasia. Can. Urol. Assoc. J. 2012; 6(5 Suppl. 2):S143-S145.
  10. Tao W., Xue B., Zang Y. et al. The application of 120-W high-performance system GreenLight laser vaporization of the prostate in high-risk patients. Lasers Med Sci. 2012 Oct 4. [Epub ahead of print].
  11. Schroeck F.R., Hollingsworth J.M., Kaufman S.R. et al. Population based trends in the surgical treatment of benign prostatic hyperplasia. J Urol. 2012;188(5):1837-1841.
  12. Морозов А.П., Морозов А.А. Фотоселективная вапоризация в лечении аденомы предстательной железы у мужчин пожилого и старческого возраста. Урология. 2012;6:74-78.
  13. Cho S.Y., Park S., Jeong M.Y. et al. 120W GreenLight High Performance System laser for benign prostate hyperplasia: 68 patients with 3-year follow-up and analysis of predictors of response. Urology. 2012;80(2):396-401.
  14. Elshal A.M., Elmansy H.M., Elhilali M.M. Can we predict the outcome of 532 nm laser photoselective vaporization of the prostate? Time to event analysis. J Urol. 2012;188(5): 1746-1753.
  15. Zang Y.C., Shan Y.X., Xue B.X. et al. Evaluation of 80-W and 120-W GreenLight laser vaporization for benign prostatic hyperplasia in high-risk patients. Zhonghua Nan Ke Xue. 2012; 18(5):436-440.
  16. Глыбочко П.В., Анафин Т.Г., Шалекенов С.Б. Первый опыт применения лазерного аппарата «UROBEAM» в лечении больных с аденомой предстательной железы в Казахстане. Урология. 2011 ;5:65-67.
  17. Когут В.В., Джуран Б.В. Первые результаты лечения больных аденомой предстательной железы с помощью диодного лазера MEDILAS D UROBEAM на Украине. Урология 2012;3:34-37.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies